



OncoBioPharm and China Summit Capital partner to develop Tensinomab for Chinese market.

Shanghai, People's Republic of China – 2 December 2013.

OncoBioPharm Ltd (OncoBioPharm) announced that it will enter into a long term strategic collaboration, development and investment programme with China Summit Capital Asset Management Group (CSC) and Shanghai Newsummit Biopharma Group Co Ltd (Newsummit).

The strategic collaboration will fund the development and commercialisation of OncoBioPharm's new anti-cancer agent, Tensinomab®, for the Chinese market. It will focus on the in-China development, the IND enabling studies and the IND filing for Tensinomab.

Under the terms of the agreement, OncoBioPharm intends to sub-license the rights for Tensinomab's development and commercialisation in China. The ongoing in-China development will be financed by investment from CSC. The collaboration will also benefit the development of Tensinomab in the other worldwide markets, where OncoBioPharm retains all rights.

An official signing ceremony was held in China Medical City and attended by representatives of OncoBioPharm, CSC, Newsummit and UK Trade and Investment.

A spokesperson for OncoBioPharm said: "We are delighted to have the opportunity to bring this new medicine to China. This collaboration marks a significant milestone in the development of Tensinomab."

About OncoBioPharm

OncoBioPharm is a biotechnology company based in Scotland, developing therapeutic antibodies that target novel pathways associated with cancer cell growth and metastasis. The company recently concluded a significant financing to complete the IND enabling programme and initiate the clinical development of Tensinomab.

About Tensinomab

Tensinomab specifically targets the N-terminus of the angiotensin II Type 1 (AT1) receptor. Many major cancers over-express the AT1 receptor, which is associated with cancer cell proliferation, tumour invasion and metastasis. Tensinomab has been shown to block cell growth, invasion and metastasis in a variety of tumour models.

About China Summit Capital Asset Management Group

CSC is focused on providing funding for a range of enterprises within the medical and healthcare industry. These include innovative pharmaceutical companies researching and developing new drugs, medical equipment and healthcare services. Through cooperation with industry clusters and all levels of government, CSC has established a venture capital fund which will soon total CNY 1.05 billion.

About Shanghai Newsummit Biopharma Group Co Ltd

Newsummit provides innovative technology services and process solutions for the development of new medicines. Through its "Platform of Chain R&D", Newsummit offers a one-stop solution covering all aspects of drug research and development. To date, Newsummit has been involved in over 450 new drug development projects.



新闻稿

OncoBioPharm 与中国华岭基金合作开发 Tensinomab 项目

上海，中华人民共和国-2013.12.2

OncoBioPharm 宣布与中国华岭资产管理有限公司及上海新生源医药集团在新药研发，投资促进方面开展长期战略合作伙伴关系，共同就 Tensinomab[®]项目在中国市场的开发和产业化提供资金。

Tensinomab 是一种新型抗肿瘤制剂，该战略合作即为主要针对 Tensinomab 项目在中国的 药物开发及 IND 的注册申报事宜。

按照该项目的合作协议，OncoBioPharm 将会授权 Tensinomab 在中国的开发及商业化权利，中国华岭资产管理有限公司的投资将用于支付项目中国开发费用。该项战略合作也将使 Tensinomab 在全球其他市场的开发受益，因为 OncoBioPharm 仍拥有 Tensinomab 该项目的全球权益。

OncoBioPharm 发言人表示：“我们很高兴有机会将这个项目带入中国，这次合作对 Tensinomab 的研发具有重要的里程碑意义。

关于 OncoBioPharm

OncoBioPharm 是一家苏格兰生物技术公司，开发用于抑制肿瘤细胞生长及新陈代谢的治疗性抗体。该公司近期进行了一轮 138 万英镑的融资用于完成 Tensinomab 项目的 IND 注册及临床研究的启动。

关于 Tensinomab

血管紧张素 III 型受体 (AT1) 的 N 端是 Tensinomab 的特异性靶点，很多主要癌症的 AT1 受体的过表达都与肿瘤细胞增殖，肿瘤入侵及细胞新陈代谢有关。Tensinomab 已显示可以对各种肿瘤模型的细胞增长，入侵及新城代谢具有抑制作用。

关于华岭资本

上海华岭投资管理有限公司专注与医药和医疗产业的投资，投资项目不限于新药研发，医疗器械的研发，医药公司、医疗服务机构及企业。通过和各级政府和国内园区的合作，上海华岭投资管理有限公司现已募集及正在募集中的医疗专项风险投资基金将达人民币十亿五千万。

关于上海新生源医药集团

上海新生源医药集团有限公司是一家中国领先的医药研发公司，为新药研发项目提供创新技术服务和各种解决方案. 建立新药孵化链式公共服务平台(Platform of Chain R&D, PCRD)，为客户提供新药研发全面解决方案和一站式集成服务。截止 2012 年底，新生源实施技术服务的项目超过 450 项。